GB Sciences, Inc. (GBLX)
OTCMKTS
· Delayed Price · Currency is USD
0.0008
0.00 (0.00%)
Mar 17, 2025, 10:38 AM EST
GB Sciences Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
366.36K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.18B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| Silence Therapeutics | 43.26M |
| BioStem Technologies | 210.49M |
GB Sciences News
- 2 years ago - Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform - GlobeNewsWire
- 2 years ago - Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations - GlobeNewsWire
- 2 years ago - Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients - GlobeNewsWire
- 2 years ago - TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit - GlobeNewsWire
- 2 years ago - Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study - GlobeNewsWire
- 2 years ago - TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference - GlobeNewsWire
- 2 years ago - Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease - GlobeNewsWire
- 2 years ago - TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article - GlobeNewsWire